A chemical and polymer manufacturer is vigorously looking to expand its business into life sciences and seeking for inorganic growth vehicles through strategic investments and acquisitions that reinforce the company’s core competencies.
The company is interested in CDMOs for the biologics field and CRO to support new drug discovery process of pharmaceutical industry. In addition to this, the firm is looking for disruptive technologies in the fields of precision medicine, stem cell biology & cell-based medicine, Microbiome, designed medical devices and In Vitro Diagnostics.
As for CDMO, startups which have unique value proposition for the pharmaceutical industry are of interest. Regarding CROs, the firm is interested in companies based in Europe or North America with positive operating income. For other technologies, the firm would like to contact startups with at least proof of concept and strong IP. The firm is interested in co-development of these technologies, co-distribution of the product offerings and sharing of profit based on the contribution from each player.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Leave a Reply